Top 10 Cardiac Marker Tests Manufacturers in China

Cardiac marker test products are core in vitro diagnostic tools for early screening, diagnosis and monitoring of cardiovascular diseases. Based on technologies like chemiluminescence and immunochromatography, they detect indicators such as troponin and NT-proBNP. China's market sees accelerated domestic substitution, with enterprises excelling in technology innovation and cost control. In 2024, the market scale reached 86 billion yuan, driven by aging and graded diagnosis policies.

1. Hangzhou Biotest Biotech Co., Ltd

Biotest was established in 2008 with headquarters located in the natural scenic Eco-Industrial Park Yuhang District of Hangzhou city. Our flagship facility consists of an area of 85,000 square meters with registered capital of 106 million RMB.
Hangzhou Biotest Biotech Co., Ltd. supplies major IVD categories: fertility health, drug testing/toxicology, infectious disease identification, tumor marker detection and cardiac marker monitoring. Biotest harnesses the world-leading technologies of bioengineering by using gene recombinant antigens, synthetic antigens, mono-specific antibodies and polyclonal antibodies combined with latex and colloidal metal particles on immuno-chromatographic assay scaffold to accomplish our test development goals.

2. Mindray Medical International Limited

A domestic IVD giant with a full cardiac marker product line. It integrates equipment and reagents, dominating 28% of the market in 2024, with high-performance chemiluminescence kits and supporting automatic analyzers.

3. Wondfo Biotech Co., Ltd

Strong in high-sensitivity detection technology, its hscTn reagent sensitivity reaches 0.003ng/mL, covering 85% of tertiary hospitals, with 2023 cardiac diagnostic revenue accounting for 62% of its segment.

4. Getein Biotech, Inc.

Focuses on primary markets, launching cost-effective fluorescence immunochromatography platforms, with over 38% market share in county hospitals and 28,000 device installations in primary institutions.

5. Antu Bio-Engineering Co., Ltd

Engaged in chemiluminescence-based cardiac marker kits, its products cover hscTnT and NT-proBNP, with global sales reaching 1.5 billion yuan in 2024 and expanding international presence.

6. Neobio Technology Co., Ltd

An innovator in the industry, expected to lead the market by 2030. It strengthens R&D in intelligent detection products, with products widely used in tertiary hospitals.

7. Di Rui Medical Co., Ltd

A pioneer in domestic substitution, its high-precision cardiac marker kits rank among top market shares, with stable performance in chemiluminescence and conventional detection fields.

8. Beijing Strong Biotech Co., Ltd

Holds 19% of the market in 2024, focusing on cardiac enzyme spectrum and troponin detection kits, with mature supply chains and extensive channel coverage.

9. Phygene Biotech Co., Ltd

Excels in antibody R&D via directed evolution technology, supplying high-sensitivity cardiac marker antibodies with 0.1ng/mL sensitivity, supporting upstream industry development.

10. Sunnyvale Bio-Tech Co., Ltd

Specializes in multi-marker combined detection kits, leveraging technological advantages in chemiluminescence to provide integrated diagnostic solutions for clinical institutions.